Effect of Exendin-(9-39) On Glucose Requirements To Maintain Euglycemia



Status:Recruiting
Conditions:Endocrine
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:Any
Updated:10/11/2018
Start Date:February 2009
End Date:December 2019
Contact:Stephanie Givler, BS,CCRC
Email:givler@email.chop.edu
Phone:267-426-7622

Use our guide to learn which trials are right for you!

Role of GLP-1 In Congenital Hyperinsulinism: Effect Of Exendin-(9-39)On Glucose Requirements To Maintain Euglycemia

The purpose of this study is to examine the effect of exendin-(9-39)on glucose requirements
to maintain euglycemia in infants with congenital hyperinsulinism unresponsive to medical
therapy

This is an open label sudy to examine the effect of exendin-(9-39)on glucose requirements to
maintain euglycemia in infants with congenital hyperinsulinism unresponsive to medical
therapy and to determine therapeutic plasma levels,plasma half life and pharmacokinetics of
exendin-(9-39)

Inclusion Criteria:

- Confirmed diagnosis of congenital hyperinsulinism (based on clinical criteria:
insulin, beta hydroxybutyrate, and/or free fatty acid plasma levels at the time of
hypoglycemia, and/or glycemic response to glucagon at the time of hypoglycemia)

- Age: from birth to 12 months

- Failure to respond to diazoxide (defined as the failure to maintain blood glucose and
octreotide (defined as the failure to maintain blood glucose ≥ 70 mg/dL without
supraphysiologic rates of glucose infusion> 4-5 mg/Kg/min)

Exclusion Criteria:

- Evidence of a medical condition that might alter results, including active infection,
kidney failure, severe liver dysfunction, severe respiratory or cardiac failure

- Current therapy at the time of initiation of study procedures with medications that
affect glucose metabolism, such as high dose glucocorticoids, ß-agonists, glucagon,
diazoxide and octreotide. Subjects will be eligible to participate 4 hours after
glucagon is discontinued, 24 hours after the last dose of octreotide and 72 hours
after last dose of diazoxide,

- Subjects with suspected Beckwith-Wiedemann syndrome or other syndromic forms of
congenital hyperinsulinism.
We found this trial at
1
site
South 34th Street
Philadelphia, Pennsylvania 19104
 215-590-1000
Principal Investigator: Diva D De Leon, MD
Phone: 267-426-7622
Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials